Physician profile
Ajay Kwatra
NPI 1215024195
$9,548.35
in general payments reported to CMS, 2019-2025
26 companies · $1,143 in 2025
The $1,143 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,784 · 2020: $842 · 2021: $2,309 · 2022: $1,586 · 2023: $363 · 2024: $523 · 2025: $1,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,028.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $4,826.99 | 2019-2025 | Titan |
| Axonics, INC. | $2,688.45 | 2020-2024 | Axonics |
| Astellas Pharma US INC | $397.60 | 2019-2024 | Xtandi, Myrbetriq |
| Procept Biorobotics Corporation | $227.98 | 2024-2025 | Aquabeam System |
| Pfizer INC. | $165.14 | 2019-2024 | |
| Teleflex LLC | $138.02 | 2022 | |
| Boston Scientific Corporation | $132.41 | 2020-2025 | Spaceoar Vue System - 10ml, Axonics |
| Forte Bio-Pharma LLC | $125.00 | 2022 | |
| Mckesson Medical-Surgical, INC. | $93.50 | 2019 | |
| Siemens Medical Solutions USA, INC. | $88.83 | 2025 | Truebeam |
| Antares Pharma, INC. | $65.19 | 2022-2024 | Xyosted |
| Urogen Pharma, INC. | $64.71 | 2025 | |
| Ferring Pharmaceuticals INC. | $63.49 | 2019-2025 | Adstiladrin |
| Dentsply Ih INC. | $52.07 | 2022-2024 | Lofric |
| Abbvie INC. | $51.58 | 2020-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $49.80 | 2020-2022 | |
| Dentsply Ih Ab | $44.65 | 2023-2025 | Lofric, Lofric |
| Merck Sharp & Dohme LLC | $44.64 | 2024 | Keytruda |
| Novartis Pharmaceuticals Corporation | $43.55 | 2025 | |
| Karl Storz Lithotripsy-America | $36.69 | 2021 | |
| Sumitomo Pharma America, INC. | $34.47 | 2023 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $30.21 | 2025 | |
| Myriad Genetic Laboratories, INC. | $30.08 | 2024 | Prolaris |
| Urovant Sciences INC | $22.28 | 2022 | |
| Clarus Therapeutics INC. | $17.22 | 2021 | |
| Halozyme INC | $13.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Kwatra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.